PDS Biotechnology Corporation

Healthcare · Biotechnology · United States

Last price 1.55 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 112.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma...